Antheia, Inc.
Ending drug shortages with advanced biosynthesis
- Headquarters
- Menlo Park, California
- Employees
- 1–10
- Founded
- 2016
- Business Model
- B2B
- Website
- antheia.bio
- Total Funding
- $1.6M
About
Antheia, Inc. is a next-generation pharmaceutical ingredient manufacturer using synthetic biology and advanced biosynthesis to produce Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) for essential medicines. Founded by Stanford synthetic biology pioneer Dr. Christina Smolke, Antheia engineers yeast to reconstruct complex plant biosynthetic pathways—converting simple sugars into high-value pharmaceutical compounds at commercial scale via fermentation. The company has a pipeline of 70+ biosynthetic KSMs and APIs and achieved commercial-scale shipment of thebaine for use in Narcan (naloxone) production, addressing critical drug shortage vulnerabilities in the U.S. pharmaceutical supply chain.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingFunding History
No funding data available yet.
Know something? Help us improve our data.
Investors
No investor data available yet.
Similar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...